Clinical trials: Depression
Depression
A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT)
The primary purpose of this study is to assess the ability of scopolamine to improve the antidepressant effects of ECT and to determine whether scopolamine will shorten the time to response and remission for patients receiving…
- Trial name
- NCT01312844
- Testing
- Scopolamine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes, Depression
INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study
To provide better care and preventive services for people with both depression and diabetes, the investigators propose to develop and test whether interventions to reduce depressive symptoms can be integrated into routine…
- Conditions
- Diabetes, Depression, Cardiovascular Risk Factor
- Trial name
- INDEPENDENT (NCT02022111)
- Testing
- Patient Education and Behavioral Activation, Supporting Self-Care (care coordinators), Psychiatrist and Diabetologist Reviews
- Where
- 4 sites in India
- Volunteers
- 404 people
- Sponsor
- Emory University
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Insomnia, Depression
Reducing Suicidal Ideation Through Insomnia Treatment
Epidemiologic reports have linked insomnia to suicidal ideation and suicide death. However, no studies have determined whether treating insomnia decreases the risk of suicidality.
- Conditions
- Insomnia, Depression, Suicidal Ideation
- Trial name
- REST-IT (NCT01689909)
- Testing
- Zolpidem-CR
- Where
- 4 sites in United States
- Volunteers
- 103 people
- Sponsor
- Augusta University
Depression, Suicidal Ideation
BRITEPath, Component 3 of iCHART (Integrated Care to Help At-Risk Teens)
BRITEPath (BP) aims to support co-located mental health clinicians in the development of a high quality, effective, and personalized safety plan for referred patients who screen positive for depression and/or suicidal ideation.
- Trial name
- NCT04000399
- Testing
- BRITEPath
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Pittsburgh
Depression and Suicide
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
This is a rater-blinded, randomized controlled trial. All patients will receive esketamine for treatment of Major Depression with Suicidal Ideation (MDSI).
- Trial name
- ENDURE (NCT04760652)
- Testing
- Cognitive Behavioral Therapy CBT, TAU
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Yale University
Depressive Disorder, Major
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis.
- Trial name
- NCT03207438
- Testing
- Quetiapine 50 MG Extended Release Oral Tablet, Quetiapine Fumarate XR 150-300 mg
- Volunteers
- 1,790 people
- Sponsor
- University of Saskatchewan
Depression
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
This study will evaluate the effectiveness of adding motivational interviewing to antidepressant treatment for major depressive disorder in Hispanic adults.
- Trial name
- NCT00564278
- Testing
- Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Treatment Resistant Depressive Disorder
Ketamine for Treatment Resistant Late-Life Depression
The purpose of this study is to examine the effectiveness of a single infusion of ketamine (KET), to determine which dose is optimal 7 days after infusion using Bayesian Adaptive Randomization, and to learn about how ketamine…
- Trial name
- NCT02556606
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- VA Office of Research and Development
Depression, Anxiety
Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor (SPEAC) for Adults With Emotional Distress (Phase 1)
In the phase 1 of the SPEAC project the specific aims are to: (1) establish the functionality, usability, and treatment fidelity of Lumen using iterative, user-centered design, development, and formative evaluation; and (2)…
- Trial name
- SPEAC (NCT04524104)
- Testing
- Lumen Treatment
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- University of Illinois at Chicago
Bipolar Disorder, Bipolar Depression
Uridine Adolescent Bipolar Depression Randomized Controlled Trial
This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for depressed adolescents with bipolar disorder (i.e. "bipolar depression").
- Conditions
- Bipolar Disorder, Bipolar Depression, Manic Depression
- Trial name
- NCT01805440
- Testing
- Uridine
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- University of Utah
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Recurrent Major Depressive Disorder With Atypical Features
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
- Trial name
- NCT00585585
- Testing
- betahistine dihydrochloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Depression, Child Development
Healthcare Providers as Trusted Messengers to Increase Receipt of Tax Credits Among Low-income Families
The purpose of this study is to pilot test the feasibility and preliminary efficacy of healthcare provider referrals to a tax filing app within parent-child health programs to test whether such referrals can increase receipt of…
- Conditions
- Depression, Child Development, Stress, Physical Illness
- Trial name
- NCT05612685
- Testing
- Healthcare provider referral to a tax filing app
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Depression, Anhedonia
DTA (Dopaminergic Therapy for Anhedonia) Study
The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia.
- Trial name
- NCT04723147
- Testing
- Carbidopa Levodopa
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Emory University
Neonatal Death, Perinatal Death
Leveraging Interactive Text Messaging to Monitor and Support Maternal Health in Kenya
Mobile health (mHealth) interventions such as interactive short message service (SMS) text messaging with healthcare workers (HCWs) have been proposed as efficient, accessible additions to traditional health care in…
- Conditions
- Neonatal Death, Perinatal Death, Depression
- Trial name
- AI-NEO (NCT05369806)
- Testing
- Interactive two-way SMS dialogue
- Where
- 2 sites in Kenya
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Washington
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder.
- Trial name
- NCT00863798
- Testing
- Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg
- Where
- 24 sites in United States
- Volunteers
- 682 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.